Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology

AIDS

Volumn 13, Issue 10, 1999, Pages 1151-1158

  Del Amo, Julia ^a   Malin, Adam S ^b   Pozniak, Anton ^c   De Cock, Kevin M ^d,e  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b LONDON CHEST HOSPITAL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

HIV; Progression; Survival; Tuberculosis

Indexed keywords

CD4 ANTIGEN; CYTOKINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; SURVIVAL; TUBERCULOSIS; VIRUS REPLICATION;

DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 0032788374     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907090-00002     Document Type: Review

References (91)

1. 1. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphism. N Engl J Med 1992, 326:231-235.
2. 2. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993, 328:1137-1144.
3. 3. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection, N Engl J Med 1989, 320:545-550.
4. 4. Barnes PF, Bloch AB, Davidson PT, Snider DE. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991, 324:1644-1650.
5. 5. De Cock KM, Soro B, Coulibaly IM, Lucas SB. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992, 268:1581-1587.
6. 6. Folks TM, Justement J, Kinter A, et al. Characterisation of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol 1988, 86:2365-2368.
7. 7. Clouse KA, Powell D, Washington I, et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 1989, 42:431-438.
8. 8. Michihiko S, Yamamoto N, Shinozaki F, et al. Augmentation of in-vitro HIV replication in peripheral blood mononuclear cells of AIDS and ARC patients by tumour necrosis factor [letter]. Lancet 1989, 1:1206-1207.
9. 9. Folks TM, Justement J, Kinter A, et al. Cytokine induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987, 238:800-802.
10. 10. Potts BJ, Maury W, Martin MA. Replication of HIV-1 in primary monocyte cultures. Virology 1990, 175:465-476.
11. 11. Griffin GE, Leung K, Folks TM, Kunkel S, Nabel GJ. Activation of HIV gene expression during monocyte differentiation by induction of NF kappa B. Nature 1989, 339:70-73.
12. 12. Poli G, Kinter A, Justement JS, et al. Tumour necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A 1990, 87:782-785.
13. 13. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumour necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991, 173:699-703.
14. 14. Fazely F, Dezube BJ, Allen Ryan J, Pardee AB, Ruprecht RM. Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in culture. Blood 1991, 77:1653-1656.
15. 15. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987, 326:711-713.
16. 16. Osborn L, Kunkel S, Nabel GJ. Tumour necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B, Proc Natl Acad Sci U S A 1989, 86:2336-2340.
17. 17. Greene WC. The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med 1991, 324:308-17.
18. 18. Rosenberg ZF, Fauci AS. Immunopathogenesis of HIV infection. FASEB J 1991, 5:2382-2390.
19. 19. Tong Starksen SE, Luciw PA, Peterlin BM, Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc Natl Acad Sci U S A 1987, 84:6845-6848.
20. 20. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumour necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A 1989, 86:5974-5978.
21. 21. Harada S, Koyanagi Y, Nakashima H, Kobayashi N, Yamamoto N. Tumour promoter TPA, enhances replication of HTLV-III/LAV. Virology 1986, 154:249-258.
22. 22. Koyanagi Y, O'Brien WA, Zhao JQ, Golde DW, Gasson JC, Chen IS. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 1988, 241:1673-1675.
23. 23. Wallis RS, Amir Tahsabben M, Fllner JJ. Induction of interleukin 1 and tumour necrosis factor by mycobacterial proteins: the monocyte Western blot. Proc Natl Acad Sci USA 1990, 87:3348-3352.
24. 24. Valone SE, Rich EA, Wallis RS, Ellner JJ. Expression of tumour necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens. Infect Immun 1988, 56:3313-3315.
25. 25. Barnes PF, Chatterjee D, Abrams JS, et al. Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. J Immunol 1992, 149:541-547.
26. 26. Moreno C, Taverne J, Mehlert A, et al. Lipoararbinomanan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages. Clin Exp Immunol 1989, 76:210-245.
27. 27. Ogawa I, Uchida H, Kusumoto Y, Mori Y, Yamamura Y, Hamada S. Increase in tumour necrosis factor alpha-and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with Mycobacterium tuberculosis. Infect Immun 1991, 59:3021-3025.
28. 28. Takashima T, Ueta C, Tsuyuguchi I, Kishimoto S. Production of tumour necrosis factor alpha by monocytes from patients with pulmonary tuberculosis. Infect Immun 1990, 58:3286-3292.
29. 29. Kindler V, Sappino AP, Grau GF, Piguet PF, Vassalli P. The inducing role of tumour necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989, 56:731-740.
30. 30. Zhang Y, Doerfler M, Lee TC, Guillemin B, Rom WN. Mechanisms of stimulation of interleukin-1 beta and tumour necrosis factor-alpha by Mycobacterium tuberculosis components. J Clin Invest 1993, 91:2076-2083.
31. 31. Wallis RS, Fujiwara H, Ellner JJ. Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. Infect Immun 1986, 56:3313-3315.
32. 32. Chensue SW, Davey MP, Remick DG, Kunkel SL. Infect Release of interleukin-1 by peripheral blood mononuclear cells in patients with tuberculosis and active inflammation. Infect Immun 1986, 52:341-343.
33. 33. Wallis RS, Vjecha M, Amir Lahmasseb M, et al. Influence of tuberculosis on human immunodeficency virus (HIV-1), enhanced cytokine expression and elevated beta 2 microglobulin in HIV-1 associated tuberculosis. J Infect Dis 1990, 167:43-48.
34. 34. Garrait V, Cadranel J, Esvant H, et al. Tuberculosis generates a microenvironment enhancing the productive infection of local lymphocytes by HIV. J Immunol 1997, 159:2824-2830.
35. 35. Schaul V, Rom WN, Smith KA, et al. Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. Infect Dis 1993, 168:1056-1059.
36. 36. Zhang Y, Nakata K, Weiden M, Rom WN. Mycobacterium tuberculosis enhances human immunodeficiency virus 1 replication by transcriptional activation at the long terminal repeat. J Clin Invest 1995, 95:2324-2331.
37. 37. Shattock RJ, Friedland JS, Griffin GF. Modulation of HIV transcription in and release from human monocytic cells following phagocytosis of Mycobacterium tuberculosis. Res Virol 1993, 144:7-12.
38. 38. Lederman MM, Georges DL, Kusner DJ, Mudido P, Giam CZ, Loossi Z. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. J Acquired Immune Defic Syndr 1994, 7:727-733.
39. 39. Vanham G, Edmonds K, Qing L, et al. Generalised immune activation in pulmonary tuberculosis: co-activation with HIV infection. Clin Exp Immunol 1996, 136:193-196.
40. 40. Loossi Z, Sierra Madero JG, Blinkhorn RA, Mettler MA, Rich EA. Enhanced susceptibility of blood monocytes from patients with pulmonary tuberculosis to productive infection with human immunodeficiency virus type 1. J Exp Med 1993, 177:1511-1516.
41. 41. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquired Immune Defic Syndr Hum Retrovirol 1996, 11:247-257.
42. 42. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996, 157:1271-1278.
43. 43. Manoff SB, Farzadegan H, Mun̄oz A, et al. The effect of latent Mycobacterium tuberculosis infection on human immunodeficiency virus (HIV) disease progression and HIV RNA load among injecting drug users. J Infect Dis 1996, 174:299-308.
44. 44. Beck JS, Potts RG, Kardijito T, Grange JM. T4 lymphopenia in patients with active pulmonary tuberculosis. Clin Exp Immunol 1985, 60:49-54.
45. 45. Lurrett GS, Telzak FF. Normalisation of CD4+ T lymphocyte depletion in patients without HIV infection treated for tuberculosis. Chest 1994, 105:1335-1337.
46. 46. Singhal M, Shimokata KK, Awachi H, Kishimoto H, Maeda F, Ito Y. Local cellular immunity in tuberculous pleurisy. Am Rev Respir Dis 1982, 126:822-824.
47. 47. Ainsley GM, Solomon JF, Bateman ED. Lymphocyte and lymphocyte subset numbers in blood, in bronchoalveolar lavage and pleural fluid in various forms of human pulmonary tuberculosis at presentation and during recovery. Thorax 1992, 47:513-518.
48. 48. Smith DK, Neal JI, Holmberg SD, and the Centers for Disease Control Idiopathic CD4+ T-lymphocyte task Force. Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. N Engl J Med 1993, 328:373-379.
49. 49. Djomand D, Diaby L, N'Gbichi JM, et al. Idiopathic CD4+ T-lymphocyte depletion in a West African population. AIDS 1994, 8:843-847.
50. 50. Donovan RM, Bush CE, Markowitz NP, Baxa DM, Saravolatz LD. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J infect Dis 1996, 174:401-403.
51. 51. Schoenbaum FF, Farzadegan H, Gourevitch MN, Alpert P, Margolick I. The effect of bacterial pneumonia on HIV viral load and T cell phenotypes. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, 22-26 January 1997 [abstract 119].
52. 52. Greenblatt R, Wieder E, Karliner L, et al. HIV-1 RNA levels and expression of immune activation markers among adults during common acute infections and convalescence. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, 22-26 January 1997 [abstract 116].
53. 53. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997, 176:766-770.
54. 54. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222-1230.
55. 55. Glesby MJ, Hoover DR, Farzadegan H, et al. The effect of influenza vaccination in human immunodeficiency virus type 1 load: a randomized, double blind, placebo-controlled study. J Infect Dis 1996, 174:1332-1336.
56. 56. Tasker S, O'Brien W, Rosetti A, et al. Effects of influenza vaccination in HIV-infected patients: a double-blinded, placebo-controlled trial. 35th Interscience conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract 1B-11].
57. 57. Whalen C, Horsburgh R, Hom D, Laharl C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Crit Care Med 1995, 151:129-135.
58. 58. Leroy V, Salmi RL, Dupon M, et al. Progression of human immunodeficiency virus infection in patients with tuberculosis disease. A cohort study in Bordeaux, France 1988-1994. Am J Epidemiol 1997, 45:293-300.
59. 59. Turner BJ, Markson LE, McKee L, Houchens R, Fanning T. The AIDS-defining diagnosis and subsequent complications: a survival-based severity index. J Acquired Immune Defic Syndr 1991, 4:1059-1071.
60. 60. Chequer P, Hearst N, Hudes ES, et al. Determinants of survival in adult Brazilian AIDS patients, 1982-89. AIDS 1992, 6:483-487.
61. 61. Lundgren JD, Pedersen C, Clumeck N, et al. Survival differences in European patients with AIDS, 1979-89. BMJ 1994, 308:1068-1073.
62. 62. Mocroft AJ, Johnson MA, Sabin CA, et al. Clinical staging system for AIDS patients. Lancet 1995, 346:12-17.
63. 63. Petruckevitch A, Del Amo J, Phillips AN, et al. Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London. AIDS 1996, 12:1007-1013.
64. 64. Piette JD, Intrator O, Zierler S, Mor V, Stein MD. An exploratory analysis of survival with AIDS using a non-parametric tree-structures approach. Epidemiology 1992, 3:310-318.
65. 65. Caylà JA, Artacoz L, Iglesias B, Jansa JM, Plasencia A. The epidemiology of AIDS in Barcelona (1981-1991). A study of mortality and survival. Med Clin Barc 1994, 102:129-135.
66. 66. Alberdi JC. AIDS surveillance 1992, 29-32: Report no. 9 Autonomous region of Madrid, Spain.
67. 67. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17);1-19.
68. 68. Del Amo J, Petruckevitch A, Phillips AN, et al. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998, 12:1203-1209.
69. 69. Mukadi V, Perriens JH, St Louis ME, et al. Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet 1993, 342:143-146.
70. 70. Ackah A, Coulibaly D, Digbeu H, et al. Response to therapy, mortality, and CD4+ lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'lvoire. Lancet 1995, 345:607-610.
71. 71. Martin DJ, Sim JG, Sole GJ, et al. CD4+ lympohocyte count in African patients co-infected with HIV and tuberculosis. J Acquired Immune Defic Syndr Hum Retrovirol 1995, 8:386-391.
72. 72. Perneger TV, Sudre P, Lundgren JD, et al. for the AIDS in Europe Study Group. Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. BMJ 1995, 311:1468-1471.
73. 73. Mocroft AJ, Lundgren JD, Monforte AD, et al. Survival of AIDS patients according to type of AIDS-defining event. Int J Epidemiol 1997, 26:400-407.
74. 74. De Cock KM, Lucas SB, Lucas S, Agness J, Kadio A, Gayle HD. Clinical research, prophylaxis, therapy, and care for HIV disease in Africa. Am J Public Health 1993, 83:1385-1389.
75. 75. De Cock KM, Binkin NJ, Zuber PLF, Tappero JW, Castro KG. Research on HIV-associated tuberculosis in resource-poor countries. JAMA 1996, 276:1502-1507
76. 76. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993, 7:1569-1579.
77. 77. Kaplan JE, Hu DJ, Holmes KK, Jaffe HW, Masur H, De Cock KM. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. Am J Trop Med Hyg 1996, 55:1-11.
78. 78. Greenberg AE, Lucas SB, Tossou O, et al. Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Cote d'lvoire. AIDS 1995, 9:1251-1254.
79. 79. Grant AD, Djomand G, De Cock KM. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS 1997, 11 (Suppl. B):S43-S54.
80. 80. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993, 342:268-272.
81. 81. Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997, 11:875-882.
82. 82. Mwinga AG, Hosp M, Godfrey-Faussett P, et al. Randomized placebo controlled trial of two intermittent regimens in the prevention of HIV-related tuberculosis in Lusaka, Zambia [abstract]. Int J Tubercl Lung Dis 1997, 1 (Suppl.):511-PA04.
83. 83. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997, 337:801-808.
84. 84. Lucas SB, De Cock KM, Hounnou A, et al. Contribution of tuberculosis to slim disease in Africa. BMJ 1994, 308:1531-1533.
85. 85. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomised controlled trials. AIDS 1999, 13:501-507.
86. 86. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomized placebo controlled trials. BMJ 1998, 317:625-629.
87. 87. Canetti G. Endogenous reactivation and exogenous reinfection. Their relative importance with regard to the development of non-primary tuberculosis. Bull Int Un Tubercl 1972, 47:116-122.
88. 88. Styblo K. Epidemiology of tuberculosis-Selected papers. The Royal Netherlands Tuberculosis Association, the Hague, Netherlands, 1991.
89. 89. Mellors JW, Rinalod CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
90. 90. Alaeus A, Lidman K, Sonnerborg A, Albert J. Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS 1997, 11:859-865.
91. 91. Cohn DL, O'Brien RJ. The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. Int J Tubercl Lung Dis 1998, 2:16-26.